Fig. 8: In vivo PIT efficiency of NanoNMO in combination with PD-1 antibody. | Nature Communications

Fig. 8: In vivo PIT efficiency of NanoNMO in combination with PD-1 antibody.

From: Phthalocyanine aggregates as semiconductor-like photocatalysts for hypoxic-tumor photodynamic immunotherapy

Fig. 8

Biochemical analysis of a CRT (***p < 0.0001), b ATP (***p < 0.0001), c HMGB-1 (***p < 0.0001), d IL-2 (***p < 0.0001), e IL-6 (***p < 0.0001), f TNF-α (***p < 0.0001) and g IFN-γ (***p < 0.0001) in the serum of mice 24 h after different treatments. n = 5 biologically independent experiments for mice. h Schematic outline of the establishment of a 4T1 bilateral tumor model and the treatment steps and procedures for different treatments. Created in BioRender. Liu, H. (2024) BioRender.com/w77z183. PDT treatment was performed 8 h after intravenous injection of NanoNMO with a 685 nm laser (100 mW·cm−2, 5 min), followed by intravenous injection of αPD-1 (2.5 mg·kg-1) on the first and third days, respectively. Tumor volume was continuously monitored until day 14, after which mice were sacrificed for further biochemical studies. Tumor growth plots of i primary tumors (Group 1:***p < 0.0001, Group 5:***p < 0.0001, *p = 0.0268) and j distant tumors (***p < 0.0001, **p = 0.0045) in 4T1 tumor-bearing mice following the indicated treatments. Average weights of k primary tumors (***p < 0.0001, **p = 0.0046, *p = 0.0164) and l distant tumors (***p < 0.0001, **p = 0.0020) following different treatments. m Average body weight changes of mice after different treatments. n Representative tumor images of primary tumors and distant tumors of mice after 14 d of indicated treatments. n = 5 biologically independent experiments for mice. The quantitative data of the population of DC maturation (CD11c+ CD80+ CD86+) in o primary tumors (Group 6: ***p < 0.0001, Group 4: ***p = 0.0046, **p = 0.0080), p distant tumors (Group 6: ***p < 0.0001, Group 5: ***p < 0.0001, Group 4: ***p < 0.0001, **p = 0.0096) and q lymph nodes (Group 6: ***p < 0.0001, Group 5: ***p < 0.0001, Group 5: **p = 0.0038, Group 1–3: **p = 0.0018) of mice after the indicated treatments. The quantitative data of CD4+ T lymphocytes in r primary tumors (***p < 0.0001), s distant tumors (***p < 0.0001) and t spleen (***p < 0.0001) of mice after the indicated treatments. The quantitative data of CD8+ T lymphocytes in u primary tumors (***p < 0.0001, **p = 0.0011), v distant tumors (***p < 0.0001) and w spleen (***p < 0.0001) of mice after the indicated treatments. n = 5 biologically independent experiments for mice. x Schematic illustration of the PIT synergistic process of NanoNMO and αPD-1. Created in BioRender. Liu, H. (2024) BioRender.com/r19s666. Data were expressed as mean values ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, determined by two-tailed Student’s t test.

Back to article page